Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston


You May Also Like

Results of interventional study support the use of suPARnostic® Quick Triage in emergency departments

Press Release                                                                                                                                    Birkerød, 10 September 2018 Today, at the 12th European Congress of Emergency ...